Cross-sectional Study of Bisphosphonate Use in Dermatology Patients Receiving Long-term Oral Corticosteroid Therapy

Liu, Rosemarie H.; Albrecht, Joerg; Werth, Victoria P.

doi:10.1001/archderm.142.1.37

Cited by 22 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For GIO prevention, patients who receive glucocorticoids for a long period of time may need to take antiosteoporotic drugs. Bisphosphonates (including alendronate, risedronate, ibandronate, and zoledronate) seem to be the most prescribed drugs for reducing bone resorption caused by glucocorticoids (Liu et al 2006). These medications suppress protein prenylation by inhibiting farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway, and cause disruption of the ruffled border and apoptosis of osteoclasts (Luckman et al 1998).…”

Section: Introductionmentioning

confidence: 99%

Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate

Derakhshanian

Djalali

Djazayery

et al. 2013

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

Glucocorticoid-induced osteoporosis (GIO) is the most common type of secondary osteoporosis. The aim of this study was to compare the efficacy of quercetin, a plant-derived flavonoid, with alendronate in the prevention of GIO. Fifty-six Sprague-Dawley rats were randomly distributed among 7 groups (8 rats per group) and treated for 6 weeks with one of the following: (i) normal saline; (ii) 40 mg methylprednisolone sodium succinate (MP)/kg body mass; (iii) MP + 40 μg alendronate/kg; (iv) MP + 50 mg quercetin/kg; (v) MP + 40 μg alendronate/kg + 50 mg quercetin/kg; (vi) MP + 150 mg quercetin/kg; and (vii) MP + 40 μg alendronate/kg + 150 mg quercetin/kg. MP and alendronate were injected subcutaneously and quercetin was administered by oral gavage 3 days a week. At the end of the study, femur breaking strength was significantly decreased as a consequence of MP injection. This decrease was completely compensated for in groups receiving 50 mg quercetin/kg plus alendronate, and 150 mg quercetin/kg with or without alendronate. Quercetin noticeably elevated osteocalcin as a bone formation marker, while alendronate did not show such an effect. In addition, administration of 150 mg quercetin/kg increased femoral trabecular and cortical thickness by 36% and 22%, respectively, compared with the MP-treated group. These data suggest that 150 mg quercetin/kg, alone or in combination with alendronate, can completely prevent GIO through its bone formation stimulatory effect.

show abstract

Section: Introductionmentioning

confidence: 99%

Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate

Derakhshanian

Djalali

Djazayery

et al. 2013

Can. J. Physiol. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…We believe that the alendronate contributed to the steady tapering of PSL dose compared to conventional therapy 3 . In addition, bisphosphonate use in patients receiving long‐term oral corticosteroid is recommended for prevention of osteoporosis 9 . Combined with evidence on the management of MRH thus far reported, the clinical response of our present case is valuable.…”

mentioning

confidence: 75%

Treatment trial of multicentric reticulohistiocytosis with a combination of predonisolone, methotrexate and alendronate

Satoh¹,

Oyama

Yamada

et al. 2008

The Journal of Dermatology

View full text Add to dashboard Cite

“…Liu et al. 6 conducted a cross‐sectional study of 35 patients with chronic skin disease on prolonged steroid treatment, and reported that 28 (80%) were not receiving any BP treatment.…”

Section: Reportmentioning

confidence: 99%

“…Liu et al 6 conducted a cross-sectional study of 35 patients with chronic skin disease on prolonged steroid treatment, and reported that 28 (80%) were not receiving any BP treatment. A recent Japanese population-based study showed a gender difference in bone metabolic markers such as DPD, with women having higher values.…”

Section: Reportmentioning

confidence: 99%

Preliminary study of etidronate for prevention of corticosteroid-induced osteoporosis caused by oral glucocorticoid therapy

Furukawa

Kaminaka

Ikeda

et al. 2011

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Glucocorticoids (GCs) are widely used for the treatment of various diseases, particularly in dermatology. However, there have been few reports about the outcome of treatment for GC-induced osteoporosis in patients with dermatological conditions receiving oral GCs. The present study was undertaken to prospectively evaluate the usefulness of etidronate for preventing steroid-induced osteoporosis in patients on prolonged GC therapy as routine clinical management. In total, 110 patients receiving oral GC therapy were enrolled into the study. Of these, 87 patients were evaluated (44 patients with collagen diseases, 13 patients with autoimmune bullous dermatoses, 19 patients with chronic eczema/dermatitis, 2 patients with toxicoderma/drug eruption and 9 others). Urinary deoxypyridinoline (DPD) was evaluated as a marker of bone resorption, and serum bone-specific alkaline phosphatase (BAP) as a marker of bone formation. Significant increases in urinary DPD were seen in the control group after oral GC therapy had been continued for ≥ 1 year. Treatment with etidronate suppressed this increase. When the patients were stratified according to gender, this improvement was more obvious in women. No significant difference in serum BAP level was found between the two groups. These results suggest that bisphosphonates may be useful for preventing steroid-induced osteoporosis in dermatology patients (particularly women) receiving oral GC therapy.

show abstract

Cross-sectional Study of Bisphosphonate Use in Dermatology Patients Receiving Long-term Oral Corticosteroid Therapy

Cited by 22 publications

References 24 publications

Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate

Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate

Treatment trial of multicentric reticulohistiocytosis with a combination of predonisolone, methotrexate and alendronate

Preliminary study of etidronate for prevention of corticosteroid-induced osteoporosis caused by oral glucocorticoid therapy

Contact Info

Product

Resources

About